Putrino Lab

We make people (and technology) better at Mount Sinai. Opinions are my own.

[Putrino Lab @PutrinoLab]

With some new followers on board, I wanted to take the time to re-introduce myself to the #LongCovid community (and everyone else). I’m David Putrino: Director of Rehab Innovation at @MountSinaiNYC, Associate Prof at @MountSinaiRehab for @IcahnMountSinai 1/

[CoRE at Mount Sinai @CoRESinai]

Next #AMA with @PutrinoLab this Friday at 1:30pm Eastern, 10:30am Pacific! Come ready with all questions #LongCOVID, #MECFS, #chronicLyme, etc -- we'll be live streaming on Instagram @coresinai

[charlos @loscharlos]

Hey @WIRED @AlanLevinovitz — this study was **just replicated**👇

[Putrino Lab @PutrinoLab]

I highly urge folks to listen to this incredible and informative podcast episode. We NEED people appropriately dosed with doxy after a tick bite. In many Lyme-endemic areas in the northeast, almost all ticks now carry Lyme and it can spread mins-hrs, not days, after the bite

[Dana Parish @danaparish]

🚨 🚨 TOP LYME DOC: ONE-DOSE DOXY FOR A TICK BITE IS “MALPRACTICE.”

🚩 🚩 DOCTORS & “INFLUENCERS”—-KNOCK IT OFF WITH THIS ONE-DOSE DOXY BULLSHIT. IS YOUR INTENTION TO HURL PEOPLE INTO CHRONIC ILLNESS????

[Eric Topol @EricTopol]

These findings are replicated in a 2nd independent study with persistence of the effect of the autoantibodies when transferred even 2 years later
https://t.co/DPDXDh9UOr

[betsy ladyzhets 📊 @betsyladyzhets]

Today @thesicktimes: Our roundup of last week's
@polybioRF Spring 2026 Symposium! A team effort by me and @mileswgriffis, covering overarching themes and a few specific talks we found notable. https://t.co/dFCqVHQMvK

[PolyBio @polybioRF]

This approach draws on evidence from the healthspan and aging field, where analogs of rapamycin have been shown to enhance antiviral interferon signaling, modulate T cell exhaustion, and improve antibody responses to vaccination. 6/

[CoRE at Mount Sinai @CoRESinai]

Participants in our rapamycin trial with @PutrinoLab @polybioRF are now eligible for an open-label extension: after they finish with the initial trial, both control + test group participants can take rapamycin under our supervision. Email [email protected] to enroll!

[PolyBio @polybioRF]

“Vitalik and the Balvi Fund have been incredible supporters of both PolyBio and the broader Long COVID research space over the years,” said Dr. Amy Proal, President of PolyBio Research Foundation. 3/

[PolyBio @polybioRF]

Breaking: Funding from Vitalik Buterin’s Balvi Fund Expands Long COVID Rapamycin Trial

PolyBio today announced new funding that is supporting an open-label extension phase in a clinical trial investigating low-dose Rapamycin as a potential treatment for Long COVID. All participants—including those initially randomized to placebo—will receive low-dose rapamycin during a defined follow-up period. 1/

[charlos @loscharlos]

“Given that nearly everyone in the US is believed to have had COVID, the 16% rate extrapolated to the approximately 340 million people in the country would mean that roughly 54 million Americans developed #LongCovid.

An HHS spokesperson did not respond to a request for comment.”

[Putrino Lab @PutrinoLab]

@julia_doubleday

[Putrino Lab @PutrinoLab]

@VirusesImmunity @EricTopol @CellCellPress You’re both faster than me 🤣

[Prof. Akiko Iwasaki @VirusesImmunity]

The nociceptor neurons responsible for sensing heat in the skin were damaged shortly after the patients' IgG injection. We also see human IgG around the remaining nociceptor in the skin. Analysis by @bakermind

[Dr. Christopher Kellner · NYC Neurosurgeon @chriskellnerMD]

Very interesting long COVID research just published from @PutrinoLab at @MountSinaiNYC and Akiko Iwasaki @Yale to identify neural autoantibodies in patients with long COVID that induce symptoms when transferred to a healthy mouse. https://t.co/9I50EqaL32

[Hannah Davis @ahandvanish]

#LongCovid has not decreased from 2020-2024.

Prevalence is 13-23% of US population, increasing 0.4%-1.5% every 3 months.

Incidence was 10-29%, but began increasing in 2023.

"These findings indicate an accumulating rather than resolving disease burden." https://t.co/SZGm2NFkg0

[Putrino Lab @PutrinoLab]

As always, incredibly grateful for such a long list of world-class collaborators and, of course, our wonderful participants who volunteered to participate in this work. Excited to keep exploring this with you all! 🙏🏻

Full press release: https://t.co/m2PwL0Pjli

/end

[Putrino Lab @PutrinoLab]

Wonderful day for a new #LongCOVID paper! Thanks to an incredible collaboration with @VirusesImmunity and brilliant work done by @keylas3, we studied the effects of injecting antibodies taken from people with LC into mice compared with what happened

https://t.co/uotWM9LUEG

1/

[Putrino Lab @PutrinoLab]

driver of symptoms of a subset of people with LC, autoimmunity can happen for a lot of different reasons, including pathogen persistence, so the need for thoughtful and personalized interventional approaches in the face of these findings remain crucial to push progress fwd.
9/